Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Bullboard Posts
Comment by Redbaron2211on Dec 17, 2020 12:29am
163 Views
Post# 32125801

RE:RE:RE:RE:RE:RE:RE:RE:RE:Wally Fan club

RE:RE:RE:RE:RE:RE:RE:RE:RE:Wally Fan club I agree mrna definitely isn't a threat at the moment. They have to first understand what gene to fix before they can work on a solution. When they do they can potentially stop TD1 before it starts. This however won't help those with td1, they will still be looking for treatment. It could still be another decade before we find out the cause of TD1. In the mean time a functional cure will be very valuable to those who need treatment. I believe Moderna was doing mrna trials to grow blood vessels to help diabetes regain circulation? This seems plausible. As for valuations 2$ would be incredibly cheap the only way I could see that is if Philip wanted out now and had the support to accept a lowball offer. It's possible but I feel he has his sights on something bigger.
Bullboard Posts